PubRank

Claudia Lanvers-Kaminsky

Author PubWeight™ 20.60‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy. Pediatr Blood Cancer 2012 2.08
2 A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014 1.80
3 Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010 1.76
4 Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial. Pediatr Blood Cancer 2011 1.43
5 Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008 1.18
6 Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007 1.16
7 Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood 2011 1.10
8 Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother Pharmacol 2010 0.97
9 Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2011 0.91
10 Association of telomerase activity with radio- and chemosensitivity of neuroblastomas. Radiat Oncol 2010 0.90
11 Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010 0.89
12 Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines. Anticancer Drugs 2005 0.88
13 Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Res 2003 0.87
14 Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer 2010 0.84
15 A population pharmacokinetic model for pegylated-asparaginase in children. Br J Haematol 2009 0.83
16 Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan. J Clin Oncol 2007 0.82
17 Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs 2010 0.80
18 An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. Anticancer Drugs 2011 0.80
19 In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Anticancer Drugs 2004 0.79
20 The interaction of platinum-based drugs with native biologically relevant proteins. Anal Bioanal Chem 2012 0.75
21 Influence of cimetidine and its metabolites on Cisplatin--investigation of adduct formation by means of electrochemistry/liquid chromatography/electrospray mass spectrometry. J Chromatogr A 2013 0.75